How Long Does Semaglutide Stay in Your System?
Semaglutide has an elimination half-life of approximately 1 week, so it remains in circulation about 5 weeks after the last Ozempic dose and 5 to 7 weeks after the last Wegovy 2.4 mg dose. Here is what that means for starting, stopping, pregnancy planning, and surgery.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Semaglutide has an elimination half-life of approximately 1 week, which means it stays in the bloodstream about 5 weeks after the last Ozempic injection or tablet dose [1][3]. The Wegovy label gives a slightly longer figure: semaglutide will be present in the circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection, or the last 25 mg tablet [12]. Both oral and subcutaneous semaglutide have an elimination half-life of approximately 1 week [3][4].
That long timeline shows up in four practical places. It takes 4 to 5 weeks of regular dosing for levels to reach a steady state [1][3]. After the last dose, levels fall gradually rather than all at once. The labels call for stopping at least 2 months before a planned pregnancy [1][3][7][12]. And around surgery, current guidance has most patients continuing the drug, with the care team managing risk [10][11].
What is the half-life of semaglutide in hours and days?
The elimination half-life is approximately 1 week, or about 165 hours [1][5]. A half-life is the time it takes for the amount of drug in the blood to fall by half. Semaglutide’s half-life is what allows once-weekly injections, and it is far longer than liraglutide’s half-life of 13 to 15 hours, which requires once-daily dosing [5].
The STEP 8 trial, which compared once-weekly semaglutide 2.4 mg against once-daily liraglutide 3.0 mg, was built around that difference in dosing frequency [5]. The trial authors also noted that liraglutide’s shorter half-life may cause a more abrupt, and more noticeable, return of hunger when treatment is paused, compared with semaglutide [5].
The Ozempic label points to the same number in its overdose section: because of the long half-life of approximately 1 week, a prolonged period of observation and treatment of symptoms may be necessary [1].
Why does semaglutide stay in the body so long?
Semaglutide is designed to resist the quick breakdown that affects native GLP-1. The main protraction mechanism is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid [1]. A second modification at position 8 stabilizes the molecule against degradation by the DPP-4 enzyme [1].
Once in the blood, semaglutide is extensively bound to plasma albumin, at more than 99% [1][3]. That binding reduces renal clearance and protects the drug from metabolic degradation [1].
The body clears semaglutide mainly by breaking it down, not by filtering the intact drug out. The primary route of elimination is metabolism through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, with no single organ acting as the major route of elimination [1][9]. Only about 3% of the dose is excreted in the urine as intact semaglutide, and the apparent clearance is approximately 0.05 L/h [1].
Does the tablet leave the body faster than the injection?
No. The tablet and the injection have the same elimination half-life of approximately 1 week, and both leave the body on a similar timeline [3][4]. The Ozempic and Rybelsus tablet label states that semaglutide is present in the circulation for about 5 weeks after the last tablet dose [3].
What differs is how much of each dose gets into the blood and how fast it peaks:
| Injection (Ozempic) | Tablets (Rybelsus / Ozempic) | |
|---|---|---|
| Absolute bioavailability | 89% [1] | 0.4% to 1% (Rybelsus); 1% to 2% (Ozempic tablets) [3] |
| Time to peak concentration | 1 to 3 days post dose [1] | Approximately 1 hour after the dose [3] |
| Elimination half-life | Approximately 1 week [1] | Approximately 1 week [3] |
| Time in circulation after last dose | About 5 weeks [1] | About 5 weeks [3] |
| Albumin binding | >99% [1] | >99% [3] |
The tablet label lists an absolute clearance of approximately 0.04 L/hour in patients with type 2 diabetes, close to the approximately 0.05 L/h apparent clearance reported for the injection [1][3].
How long does it take for semaglutide to build up after starting?
Steady-state exposure is achieved after 4 to 5 weeks of once-weekly injections [1]. For tablets, steady state is also achieved after 4 to 5 weeks, in that case of daily dosing [3].
The labels build in a slow start. Ozempic begins at 0.25 mg once weekly for 4 weeks, then moves to 0.5 mg once weekly [1]. Wegovy injection also starts at 0.25 mg once weekly for 4 weeks, then steps up every 4 weeks to reach the usual maintenance dosage of 2.4 mg once weekly [12]. Wegovy tablets start at 1.5 mg once daily for 30 days, step up every 30 days, and have a maintenance dosage of 25 mg once daily [12].
What do the weeks after the last dose look like?
With a half-life of approximately 1 week, blood levels would be expected to roughly halve each week after the last dose [1]. That week-by-week halving is arithmetic worked out from the label’s half-life, not a measurement taken from individual people, so treat it as an approximation.
Effects can linger as levels fall. The Ozempic label states that semaglutide causes a delay of early postprandial gastric emptying [1]. The STEP 8 authors raised the reverse point about liraglutide: its shorter half-life may make the return of hunger more abrupt on pausing than with semaglutide [5].
What happened to weight when people stopped semaglutide?
The STEP 1 extension followed 327 participants after 68 weeks of treatment [6]. During the treatment phase, mean weight loss was 17.3% with semaglutide 2.4 mg versus 2.0% with placebo [6].
At week 68, both the drug and the lifestyle intervention were withdrawn, and participants were followed for another year [6]. By week 120, the semaglutide group had regained 11.6 percentage points of lost weight versus 1.9 percentage points for placebo, leaving a net loss of 5.6% versus 0.1% from week 0 [6]. In other words, participants regained two-thirds of their prior weight loss one year after withdrawal [6]. Cardiometabolic improvements seen during treatment reverted toward baseline at week 120 for most variables [6].
Because the extension withdrew both the drug and the lifestyle program, it cannot isolate the effect of stopping the drug alone. The authors wrote that the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements [6].
How long should the wait be before trying to get pregnant?
The labels call for a washout of at least 2 months. The Ozempic injection label instructs that it be discontinued in women at least 2 months before a planned pregnancy, due to the long washout period for semaglutide [1][2]. The Rybelsus and Ozempic tablet label carries the same instruction [3].
The Wegovy label likewise states that it should be discontinued at least 2 months before a planned pregnancy, in this case because of the potential for fetal harm and to account for the long half-life of semaglutide [7][12]. The Wegovy label also states that it should be discontinued when pregnancy is recognized [7].
Should semaglutide be stopped before surgery, endoscopy, or anesthesia?
The Ozempic label warns that pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures, and instructs patients to inform their healthcare providers of any planned surgeries or procedures [1].
Two recent guidance documents point the same direction: most patients keep taking the drug, and the care team manages the risk. A multi-society guidance released on October 29, 2024 states that most patients should continue GLP-1 drugs before elective surgery, that patients at highest risk for gastrointestinal side effects should follow a liquid diet for 24 hours before the procedure, and that point-of-care ultrasound right before the procedure is an option to assess stomach contents [11]. It notes that the escalation phase of GLP-1 treatment typically lasts 4 to 8 weeks, and that elective surgery should be deferred until that phase has passed and gastrointestinal effects have gone away [11].
A multidisciplinary consensus statement published in Anaesthesia in January 2025 recommends that patients continue GLP-1 receptor agonists throughout the peri-operative period, with risks and mitigation strategies discussed through shared decision-making [10]. That statement also notes that even one week of cessation is still linked to a high risk of residual gastric content, and that up to three weeks of cessation has been linked to increased gastric volume [10].
Whether to pause, and for how long, is a decision for the prescriber and the procedure team, not something to work out alone.
Does kidney or liver disease make semaglutide stay longer?
A renal study in 56 subjects, each given a single 0.5 mg subcutaneous dose, found these mean half-lives by kidney function group [8]:
| Kidney function group | Mean half-life (hours) |
|---|---|
| Normal | 183 |
| Mild impairment | 169 |
| Moderate impairment | 201 |
| Severe impairment | 221 |
| End-stage renal disease | 243 |
Those figures come from a single-dose study, so they do not necessarily describe people on maintenance dosing. In the same study, exposure in severe renal impairment was 22% higher than normal before adjustment, but after adjusting for sex, age, and body weight, all comparisons were within the pre-specified no-effect limits, and hemodialysis did not appear to affect the pharmacokinetics [8].
The Ozempic label states that renal impairment does not have a clinically meaningful effect on semaglutide pharmacokinetics [1]. For liver disease, a study in people with mild, moderate, and severe hepatic impairment found exposure was similar across all groups [9], and the Ozempic label recommends no dose adjustment for hepatic impairment [1].
What do the labels say about missed doses?
The long half-life is part of why the labels allow some flexibility. For Ozempic, if a dose is missed, it should be administered as soon as possible within 5 days; if more than 5 days have passed, the missed dose is skipped and the next dose is given on the regularly scheduled day [1]. The weekly dosing day can be changed as long as at least 2 days, or more than 48 hours, separate two doses [1].
For Wegovy injection, if a dose is missed and the next scheduled dose is more than 2 days away, it is administered as soon as possible; if the next scheduled dose is less than 2 days away, the dose is skipped [12]. For Wegovy tablets, a missed dose is skipped and the next dose is taken the following day [12].
Sources
- US Food and Drug Administration. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information.
- National Library of Medicine. DailyMed. OZEMPIC- semaglutide injection, solution.
- National Library of Medicine. DailyMed. OZEMPIC- oral semaglutide tablet; RYBELSUS- oral semaglutide tablet.
- StatPearls Publishing. Semaglutide. StatPearls. 2026 Jan.
- PMC. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- Diabetes, Obesity and Metabolism. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. 2022.
- National Library of Medicine. DailyMed. WEGOVY- semaglutide injection, solution.
- PMC. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
- PMC. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
- Anaesthesia. Elective peri-operative management of adults taking GLP-1 receptor agonists, GIP agonists and SGLT2 inhibitors: a multidisciplinary consensus statement. 2025.
- American Society of Anesthesiologists. New Multi-Society GLP-1 Clinical Practice Guidance Released. October 29, 2024.
- National Library of Medicine. DailyMed. WEGOVY- semaglutide injection, solution; WEGOVY- semaglutide tablet.
Frequently asked questions
What is the half-life of semaglutide in days and hours?
The elimination half-life is approximately 1 week, or about 165 hours. That is much longer than liraglutide, whose half-life is 13 to 15 hours and which is dosed once daily. Semaglutide's week-long half-life is what makes once-weekly injections possible.
How long does Ozempic stay in your system after stopping?
With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last Ozempic dose. The same roughly 5-week figure applies to Rybelsus and Ozempic tablets after the last tablet dose. Levels would be expected to roughly halve each week, though that is arithmetic from the label half-life, not a per-person measurement.
How long does Wegovy take to leave your body?
The Wegovy label states that, with an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection, or the last 25 mg tablet. The longer figure applies to the Wegovy label specifically; the Ozempic label says about 5 weeks.
Does the pill leave the body faster than the shot?
No. Oral and subcutaneous semaglutide have the same elimination half-life of approximately 1 week, and both remain in circulation about 5 weeks after the last dose. The tablet reaches peak concentration about 1 hour after the dose, while the injection peaks 1 to 3 days post dose, but clearance is similar.
How long until semaglutide reaches steady levels in the body?
Steady-state exposure is achieved after 4 to 5 weeks of once-weekly injections. For tablets, steady state is also achieved after 4 to 5 weeks, in that case of once-daily dosing. The labels start at a low dose and step up over the first month or more before reaching maintenance dosing.
How long should you wait after stopping semaglutide before trying to get pregnant?
The labels instruct that semaglutide be discontinued at least 2 months before a planned pregnancy, citing the long washout period or long half-life of the drug. The Wegovy label also states that it should be discontinued when pregnancy is recognized. Timing a stop is a decision to make with the prescribing clinician.
Should you stop semaglutide before surgery or endoscopy?
Current guidance says most patients continue GLP-1 drugs before elective surgery, with the care team managing aspiration risk through measures such as a 24-hour liquid diet for the highest-risk patients and point-of-care ultrasound. A January 2025 consensus statement likewise recommends continuing GLP-1 receptor agonists throughout the peri-operative period, with shared decision-making. The Ozempic label instructs patients to tell providers about planned procedures.
Does kidney disease make semaglutide stay in your system longer?
In a single-dose study of 56 subjects given one 0.5 mg injection, mean half-life was 183 hours with normal kidney function and 243 hours with end-stage renal disease, with values of 169 to 221 hours across the mild, moderate, and severe impairment groups. After adjusting for sex, age, and body weight, exposure differences fell within no-effect limits, and hemodialysis did not appear to affect the pharmacokinetics. The Ozempic label states renal impairment has no clinically meaningful effect on semaglutide pharmacokinetics.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.